| Title |
Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm
|
|---|---|
| Published in |
JACC, July 2018
|
| DOI | 10.1016/j.jacc.2018.04.082 |
| Pubmed ID | |
| Authors |
Bruce S. Stambler, Paul Dorian, Philip T. Sager, Douglas Wight, Philippe Douville, Diane Potvin, Pirouz Shamszad, Ronald J. Haberman, Richard S. Kuk, Dhanunjaya R. Lakkireddy, Jose M. Teixeira, Kenneth C. Bilchick, Roger S. Damle, Robert C. Bernstein, Wilson W. Lam, Gearoid O’Neill, Peter A. Noseworthy, Kalpathi L. Venkatachalam, Benoit Coutu, Blandine Mondésert, Francis Plat |
| Abstract |
There is no nonparenteral medication for the rapid termination of paroxysmal supraventricular tachycardia. The purpose of this study was to assess the efficacy and safety of etripamil nasal spray, a short-acting calcium-channel blocker, for the rapid termination of paroxysmal supraventricular tachycardia (SVT). This phase 2 study was performed during electrophysiological testing in patients with previously documented SVT who were induced into SVT prior to undergoing a catheter ablation. Patients in sustained SVT for 5 min received either placebo or 1 of 4 doses of active compound. The primary endpoint was the SVT conversion rate within 15 min of study drug administration. Secondary endpoints included time to conversion and adverse events. One hundred four patients were dosed. Conversion rates from SVT to sinus rhythm were between 65% and 95% in the etripamil nasal spray groups and 35% in the placebo group; the differences were statistically significant (Pearson chi-square test) in the 3 highest active compound dose groups versus placebo. In patients who converted, the median time to conversion with etripamil was <3 min. Adverse events were mostly related to the intranasal route of administration or local irritation. Reductions in blood pressure occurred predominantly in the highest etripamil dose. Etripamil nasal spray rapidly terminated induced SVT with a high conversion rate. The safety and efficacy results of this study provide guidance for etripamil dose selection for future studies involving self-administration of this new intranasal calcium-channel blocker in a real-world setting for the termination of SVT. (Efficacy and Safety of Intranasal MSP-2017 [Etripamil] for the Conversion of PSVT to Sinus Rhythm [NODE-1]; NCT02296190). |
X Demographics
The data shown below were collected from the profiles of 334 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 56 | 17% |
| Spain | 38 | 11% |
| Mexico | 16 | 5% |
| Venezuela, Bolivarian Republic of | 13 | 4% |
| United Kingdom | 11 | 3% |
| Argentina | 8 | 2% |
| Colombia | 8 | 2% |
| Brazil | 6 | 2% |
| Peru | 6 | 2% |
| Other | 51 | 15% |
| Unknown | 121 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 240 | 72% |
| Practitioners (doctors, other healthcare professionals) | 58 | 17% |
| Scientists | 27 | 8% |
| Science communicators (journalists, bloggers, editors) | 8 | 2% |
| Unknown | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 90 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 16 | 18% |
| Student > Ph. D. Student | 9 | 10% |
| Student > Master | 8 | 9% |
| Student > Postgraduate | 6 | 7% |
| Student > Doctoral Student | 6 | 7% |
| Other | 19 | 21% |
| Unknown | 26 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 38% |
| Nursing and Health Professions | 9 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Business, Management and Accounting | 2 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 1% |
| Other | 6 | 7% |
| Unknown | 35 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 528. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2023.
All research outputs
#47,924
of 25,769,258 outputs
Outputs from JACC
#117
of 16,934 outputs
Outputs of similar age
#983
of 343,521 outputs
Outputs of similar age from JACC
#3
of 184 outputs
Altmetric has tracked 25,769,258 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,934 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,521 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 184 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.